Karyopharm Therapeutics (KPTI) Q1 2025 earnings summary

Executive summary

• Phase 3 SENTRY trial in JAKi-naïve myelofibrosis passed futility analysis, is ~80% enrolled, and continues as planned, with top-line data expected late 2025/early 2026 and enrollment to complete by June/July 2025.

• Selinexor monotherapy in heavily pretreated myelofibrosis patients showed improvements in spleen volume, symptoms, hemoglobin, and disease modification markers.

• Commercial organization remains profitable in multiple myeloma, with demand for XPOVIO up 5% year-over-year and global approvals in over 45 countries.

• Peak U.S. revenue potential for selinexor in myelofibrosis estimated at $1 billion if approved.

• Company is exploring alternatives to extend its cash runway, with current funds expected to last into early Q4 2025 after debt repayment.

Financial highlights

• Q1 2025 total revenue was $30.0M, down from $33.1M in Q1 2024; U.S. XPOVIO net product revenue was $21.1M, impacted by a $5M increase in product return reserve due to atypical returns of expired units.

• Royalty revenue grew 57% year-over-year to $1.7M, reflecting increased global demand.

• Net loss for Q1 2025 was $23.5M ($2.77/share), improved from $37.4M ($4.85/share) in Q1 2024, driven by lower operating expenses.

• R&D expenses were $34.6M and SG&A expenses were $27.4M, both down year-over-year due to cost optimization.

• Cash, cash equivalents, and investments at quarter-end were $70.3M (down from $109.1M at year-end 2024), with cash burn highest in Q1.

Outlook and guidance

• 2025 total revenue guidance is $140–$155M, with U.S. XPOVIO net product revenue expected at $115–$130M, now tracking toward the lower end due to Q1 returns.

• R&D and SG&A expenses projected at $240–$255M for 2025, including ~$20M non-cash stock-based compensation.

• Cash runway expected into early Q4 2025 after debt repayment and liquidity covenant; exploring options to extend runway.

• Preparing for commercial launch in myelofibrosis, pending positive SENTRY trial data and regulatory approval.

• Endometrial cancer and multiple myeloma programs continue to advance, with key data readouts anticipated in 2026.